Skip to main content

Media Mentions

Both the work and the people associated with the Johns Hopkins Drug Access and Affordability Initiative (JHDAAI) make frequent appearances in the media.  We are always glad to contribute to public discourse on the topic of drug pricing.

View the latest "Media Mentions" involving the JHDAAI project team below.


  • Why can’t I get my antibiotic or cancer drugs?  Hopkins experts outline the shortages and the remedies
    A massive drug shortage has left people calling around to get prescriptions filled, settling for either half dosages or going without needed medications.   Mariana Socal and Josh Sharfstein are quoted.
    The Baltimore Banner | June 7, 2023
  • Be cautious of off-label use of stimulants with other drugs
    An increasingly common trend:  US adults who take a stimulant medication, together with other drugs that target the central nervous system, such as antidepressants, opioids, and anti-anxiety medications, according to a new study published in the journal BMJ Open.  Tom Moore is quoted.
    Neural Science | May 2, 2023
  • Almost 50% of adults taking schedule II stimulants also use other psychiatric drugs
    About half of adults who were prescribed schedule II-controlled stimulants were concurrently exposed to other CNS-active drugs, many of which have withdrawal effects, complicating discontinuation, researchers reported.  Tom Moore is quoted.
    Healio / Primary Care/Pharmacology | May 1, 2023
  • Will new FDA rules help dial back expedited drugs?
    Recent reforms could require companies to perform follow-up studies on drugs that received accelerated approval.  Josh Sharfstein is quoted.
    Undark | April 12, 2023
  • Why do pharmaceutical companies give away some expensive drugs for free?
    Why do pharmaceutical companies charge exorbitant rates for their products but then give them away for free or virtually no cost to most patients, regardless of income, through patient assistance programs.  Gerard Anderson is quoted.
    MarketPlace | March 31, 2023
  • California’s plan for cheaper insulin collides with big pharma’s price cuts
    The state awarded a $50 million contract to produce less costly treatments, but moves by major suppliers might undercut this initiative.  Mariana Socal is quoted.
    New York Times Health | March 24, 2023
  • Their child’s obesity drug was working.  Then their plan refused to pay.
    Youth obesity is an epidemic, but few insurers will cover drugs costing more than $1,300 a month for adolescents.  Gerard Anderson is quoted.
    The Washington Post Health | March 24, 2023
  • Insulin prices:  Eli Lilly cuts costs, but more needs to be done for access, affordability
    Eli Lilly will be reducing the prices of some commonly-used insulins by 70%, the pharmaceutical company announced in a news release.  The company also said it will expand its Insulin Value Program, which caps out-of-pocket costs at $35 or less per month.  Jeromie Ballreich is quoted. | March 7, 2023
  • Spending on consumer advertising for top-selling prescription drugs in US favors those with low added benefit
    A new study led by researchers at BSPH found that the share of promotional spending allocated to consumer advertising was on average 14.3 percentage points higher for drugs with low added benefit compared to drugs with high added benefit.   Michael DiStefano, Gerard Anderson, Jenny Markell, Caroline Doherty and Caleb Alexander are featured.
    Medical Xpress | February 7, 2023
  • A dangerous loophole for drug ads needs to be closed
    A loophole in prescription drug regulation exposes American consumers to false and misleading claims of drug ads via on-line businesses promoting potent drugs without accurate information about their risks and benefits.   Tom Moore and Caleb Alexander are the authors.
    Stat News | January 26, 2023
  • Why kids’ medication shortages aren’t going away
    The quick and dirty answer:  Medication shortages aren’t just an American problem, aren’t limited to children’s medications.   Mariana Socal is quoted.
    The New York Times Opinion| January 18, 2023



Read older stories in archived news